Baroness Anderson of Stoke-on-Trent (Lab)

My Lords, I would usually say I thank noble Lords, but I thank the noble Baronesses—as is our wont when we talk about issues of infected blood—for their points and their continued representation of the infected blood community with unwavering dedication. Many in your Lordships’ House have consistently ensured that the voices of the infected and affected community are given a voice in this Chamber. I particularly pay tribute to the work of the noble Baroness, Lady Brinton, the noble Baroness, Lady Campbell—I was delighted to see her in your Lordships’ House last week, and she is definitely on the road to recovery—and the noble Baroness, Lady Featherstone, who has ensured that we always have a human voice, as well, of course, as the noble Baroness, Lady Finlay. Their resolve in seeking justice for the victims of this scandal cannot be overstated, and their generosity of time to make sure that I am fully abreast of such issues has been incredibly personally beneficial. I also thank my opposite number, the noble Baroness, Lady Finn, for how constructively we have worked together on these issues to deliver for a community that rightly has limited faith and trust in government after its experiences. The onus is on all of us in your Lordships’ House to make sure that community knows we are listening. I will look in detail at the comments of the noble Baroness, Lady Brinton, whose questions were very specific, as she highlighted. It may be useful for us to have a meeting with officials. I will invite all those who have participated today to attend , but I will also reflect on the points and write in advance of it. We are here first and foremost to debate the regulations, and I will prioritise the issues raised on them in my response. I am aware of the other points that have been raised and will do my best to address those too, but obviously I will reflect on Hansard if I miss any of them. On the specific points raised, I will start with those from the noble Baroness, Lady Finlay. These are incredibly important points, and she worried me, when she gave me the detail in advance, that there was a gap that we had missed. So, to clarify for the record—I think that would be useful—someone infected as a child would receive injury, social impact, autonomy, care and basic financial loss awards in the same way as an adult. They would not receive an additional financial loss award for the years when they were aged under 16. However, they would still receive an additional financial loss award for the years when they were or will be aged 16 or over. I hope that gives a level of reassurance. In the heartbreaking situation when an infected child has passed away, a bereaved parent would receive injury, social impact and autonomy awards based on the child’s infection and infection severity. This will not change based on how old their child was when they passed away. The awards to parents are higher where their child’s infection has caused or is expected to cause an early death in the future. This includes those infected with HIV or levels 3, 4 and 5 hepatitis infections. They would also be the likely beneficiary of their child’s estate under the law of intestacy. All such would likely be the recipient of whatever injury, social impact, autonomy, care and financial loss awards are due to the child’s estate. So there is still a level of compensation, but I will make sure that I also write to the noble Baroness so that she has a copy in writing as well as from Hansard. I will touch on IBCA’s prioritisation, because that is helpful in this context. IBCA is prioritising those nearing the end of their lives because community members and representatives have highlighted how important it is for these people to start their compensation claims. “Nearing the end of life” means that a person has been told by a doctor or medical professional that they might have fewer than 12 months to live. This could be due to any medical illness or condition; it does not need to be caused directly by an infection from contaminated blood.